Mimedx (MDXG) Cost of Revenue (2011 - 2026)

Mimedx has disclosed Cost of Revenue across 16 years of filings, most recently posting $17.4 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $17.4 million, up 4.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.8 million (up 15.99% YoY), and the FY2025 annual result was $73.0 million, up 21.54% from the prior year.
• Cost of Revenue came in at $17.4 million for Q1 2026 at Mimedx, down from $19.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $19.1 million in Q4 2025 to a low of $9.9 million in Q1 2022.
• The 5-year median for Cost of Revenue is $14.8 million (2023), against an average of $14.9 million.
• Peak annual rise in Cost of Revenue reached 102.44% in 2022, while the deepest fall reached 7.34% in 2022.
• Mimedx's Cost of Revenue stood at $14.4 million in 2022, then decreased by 3.67% to $13.8 million in 2023, then rose by 22.16% to $16.9 million in 2024, then climbed by 12.69% to $19.1 million in 2025, then slipped by 8.85% to $17.4 million in 2026.
• The last three Cost of Revenue figures came in at $17.4 million (Q1 2026), $19.1 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.